INTRODUCTION
Osteoarthritis (OA) is a debilitating disease characterised by progressive degradation of articular cartilage and bone remodelling. 1 Although the exact pathogenesis remains to be elucidated, genetic studies have identified several variants associated with primary OA, such as the 7q22 containing multiple potential genes, growth differentiation factor 5 (GDF5) gene, frizzled related protein gene, deiodinase iodothyronine type II (DIO2) gene and mothers against decapentaplegic homologue 3 (SMAD3) gene. 2 Together, these genes provide evidence that endochondral ossification may be involved in OA onset. 3 Endochondral ossification is driven by growth plate chondrocytes, resulting in longitudinal skeletal growth through a combination of proliferation, extracellular matrix (ECM) secretion and hypertrophy. Subsequently, terminally differentiated chondrocytes die and are replaced with bone tissue. 4 At all stages, chondrocyte behaviour is tightly regulated by a complex network of interactions between circulating hormones, locally produced growth factors and ECM components. These chondrocytes likely play a role in bone shape and/or the quality of articular cartilage. One of the strongest stimulators of chondrocyte proliferation is growth hormone (GH), predominantly via insulinlike growth factor-1 (IGF-1) secretion. 5 This qualifies variations within GH/IGF-1 genes as obvious candidates for association studies.
The dimeric GH receptor (GHR) mediates the effect of GH on target tissues and exists in different molecular structures, depending on assortments of coding polymorphisms in the GHR gene. Three GHR variants, differing in the presence or absence of exon 3 (GHR fl−fl , GHR fl−d3 , GHR d3−d3 ), are commonly seen. Exon 3 loss (d3-GHR) results in a truncated receptor with increased GH responsiveness by enhanced signal transduction. 6 7 We hypothesise that the d3-GHR polymorphism increases OA risk by increasing (local) GH/IGF-1 activity. Therefore, we compared the effects of the d3-GHR polymorphism between cases with symptomatic generalised OA and controls. We tested for confirmation in three additional cohorts. A combined analysis was performed in women (2175 OA cases and 2623 controls).
PATIENTS AND METHODS Subjects
The discovery study was the GARP (Genetics ARthrosis and Progression) study. 8 For replication, the PAPRIKA (PAtients Prospectively Recruited In Knee and hip Arthroplasty)/RAAK (Research Articular osteoArthritis Cartilage), ACRO (acromegaly) and Rotterdam studies were used. [9] [10] [11] All patients and controls were from Dutch descent. Details of original study design and phenotype definition are described in online supplementary file 1.
Genotyping
Genomic DNA was isolated from peripheral blood according to standard procedures. In GARP, the d3-GHR polymorphism was detected as described previously, 12 based on specific amplification of the wild type (935 base pairs (bp)) and mutant (532 bp) alleles. To allow high-throughput genotyping, we assessed linkage disequilibrium (LD) between d3-GHR and single nucleotide polymorphisms (SNPs) covering the gene as determined in a GWAS, by means of Illumina 660W. GWAS details are published elsewhere. 13 Previously, only one SNP (rs6873545) was described to capture the d3-GHR polymorphism. 14 We genotyped 373 GARP subjects and 752 controls for seven other SNPs (rs4590183, rs13354167, rs7721081, rs7701605, rs4242116, rs6878512, rs10941583), all being in high LD with the d3-GHR polymorphism (see online supplementary file 2). All SNPs were in Hardy-Weinberg equilibrium. In cases and controls, rs4590183 was selected as proxy for d3-GHR genotype (r 2 =1). Throughout this report, the d3 allele of rs4590183 was designated as risk allele.
Replication cohorts: samples of the Rotterdam study were genotyped with the Illumina HumanHap 550v3 Genotyping BeadChip. GWAS details are published elsewhere. 15 Other cohorts were genotyped by mass spectrometry using the homogeneous MassARRAY system of Sequenom (San Diego, California, USA) using standard conditions.
Study design/statistical analysis
First, association with d3-GHR with OA was performed in the GARP study (men and women) since this study consists of genetically enriched patients with symptomatic OA at multiple joint sites. Subsequently, we tested for confirmation in women of three other cohorts, the PAPRIKA/RAAK ( joint replacement), acromegaly (signs of clinical and radiographic OA) and Rotterdam (severe radiographic OA) studies.
Logistic regression analyses were performed with STATA V.10.1. A dominant genotypic model was applied. To adjust for family relationships within the GARP study, robust SEs were estimated from the variance between sibling pairs. 16 Combined analyses were performed in women, using R V.2.15.0. 17 If the heterogeneity metric I 2 exceeded 25%, a random-effects model was also used, otherwise only a fixed-effects model was applied. Given that only one polymorphism was studied with well established functional effects, p<0.05 was considered as reflecting significance. Table 1 shows the phenotypic characteristics of the GARP study (discovery sample). As shown in table 2, we found evidence for association between the d3-GHR polymorphism and OA, only in women of the GARP study (OR=1.36, 95% CI 1.01 to 1.83, p=0.043). Adjustment for age and body mass index (BMI) did not significantly affect the genotypic association.
RESULTS
Since women drove the association with d3-GHR, our replication was aimed at women with symptomatic OA of the PAPRIKA/RAAK and ACRO studies, and severe radiographic OA in the Rotterdam study (table 1) . For the combined analysis, 2175 cases and 2623 controls were available, and the respective genotype frequencies are shown in online supplementary file 3. Although the association with d3-GHR was significant only in the PAPRIKA/RAAK study, the combined analysis of four studies with OA at any joint location provides evidence for association with d3-GHR, with an OR of 1.17 (95% CI 1.04 to 1.32, p=0.008), without any evidence for heterogeneity (p=0.470, I
2 =0%) (table 2) . In a sensitivity analysis excluding the discovery GARP study, the association persisted (OR=1.14, 95% CI 1.01 to 1.30, p=0.042).
When we stratified for joint site in the combined analysis (table 2), we observed consistent effect sizes of approximately 1.2-1.3 among the joint strata, being significant in hip OA cases (p=0.002), without evidence for heterogeneity ( figure 1B) . Allelic data are presented in online supplementary file 4.
DISCUSSION
In a combined analysis of 2175 female OA cases and 2623 controls, we found evidence for association between the functional d3-GHR polymorphism and symptomatic OA ( pooled OR=1.17, 95% CI 1.04 to 1.32, p=0.008), without evidence of heterogeneity and independently of age and BMI. Stratifying by joint site indicated that the association was most predominant in female cases with hip OA.
Human GH is a strong modulator of important physiological processes such as fuel homeostasis, cell differentiation and metabolic control. The GH/IGF-1 axis is essential for longitudinal skeletal growth. During growth, long bones increase in height through endochondral ossification, replacing a cartilage model by bone tissue. The main player in this process is the chondrocyte. GH is a main stimulator of chondrocyte proliferation in the growth plate, and, to a lesser extent, of ECM secretion and the hypertrophic switch of post-proliferative chondrocytes. 5 Chondrocytes in OA cartilage share a fair amount of their expressed genes with those expressed in the terminal layer of the growth plate. 3 Therefore, genes involved in skeletal morphogenesis early in life determining joint shape, might play a late-acting deleterious role towards OA. IGF-1 is associated with increased cartilage formation and laxity of peri-articular ligaments, and plays a role in osteophyte development. 18 All these changes together contribute to an altered joint geometry, eventually resulting in an arthritic joint. The d3-GHR polymorphism is hypothesised to accelerate the OA process in susceptible patients by increasing GH responsiveness and, thereby, (local) IGF-1 levels.
Typically, the OR observed in the GARP discovery study was higher when compared to the replication studies but also generally higher than large scale GWA studies, such as that of Zeggini et al. 19 This could be explained by the fact that for the GARP study we have applied a family-based sampling scheme towards the extreme spectrum of the OA phenotype, consisting of sibling pairs with both symptomatic and radiographic OA at multiple sites. In general, such a study is tailored to find genetic variants in the low frequency range with moderate to large effect sizes. Here, the GARP phenotype may have been most efficient in detecting predisposition of the d3-GHR 20 ‡OR (95% CI) and p values were calculated for the dominant genotypic model, and were presented with the minor allele (exon 3 deletion, d3) as the dominant risk allele. rs4590183 was used as proxy for the d3-GHR polymorphism in all cases and controls. The OR represents the risk of having the d3-GHR polymorphism in female OA cases versus controls, as shown for the total cohort and stratified for joint site. Logistic regression analysis is performed, applying a binary logistic model. ACRO, acromegaly patients; GARP, Genetics ARthrosis and Progression study; NA, not applicable; OA, osteoarthritis; PAPRIKA/RAAK, PAtients Prospectively Recruited In Knee and hip Arthroplasty/Research Articular osteoArthritis Cartilage (primary OA).
polymorphism, although the allele frequency is not rare. Moreover, in a sensitivity analysis excluding GARP, the association between the d3-GHR polymorphism and OA persisted, whereas the consistency of the effect sizes among the different cohorts and joint strata adds to the credibility of d3-GHR.
Several potential limitations need to be addressed. First, although the direction and effect sizes were similar in our replication cohorts, only the association in the PAPRIKA/RAAK cohort was significant. This is likely to be explained by the low number of cases in the ACRO and Rotterdam studies, providing insufficient power. Second, inclusion of acromegaly patients might introduce a bias, since disease processes in acromegalic arthropathy may differ from those in primary OA. However, since the d3-GHR polymorphism does not predispose to acromegaly itself, the inclusion of acromegalics with OA is not likely to influence our results. Merely, we expect that a general detrimental effect of GH excess on joint tissue homeostasis predisposes to OA. Finally, the unknown OA status in controls might have led to an underestimation of the reported effect.
In conclusion, we found an association between the d3-GHR polymorphism and symptomatic OA in women, especially in cases with hip OA. Being aware of the tendency of association studies to produce false-positive results, additional replication is necessary. Furthermore, studying the d3-GHR polymorphism in relation to GH profiles and IGF-1 levels could further elucidate the role of the GH/IGF-1 axis in OA.
